Detalhe da pesquisa
1.
Secukinumab demonstrates superiority over narrow-band ultraviolet B phototherapy in new-onset moderate to severe plaque psoriasis patients: Week 52 results from the STEPIn study.
J Eur Acad Dermatol Venereol
; 37(5): 1004-1016, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-36606536
2.
Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data.
Acta Derm Venereol
; 102: adv00698, 2022 Apr 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-35146532
3.
Efficacy and safety of secukinumab in moderate to severe palmoplantar pustular psoriasis over 148 weeks: Extension of the 2PRECISE study.
J Am Acad Dermatol
; 84(2): 552-554, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-32565211
4.
Effectiveness and Safety of Secukinumab for Psoriasis in a Real-World Clinical Setting in the Asia-Pacific and Middle East Regions: Results from the REALIA Study.
Dermatol Ther (Heidelb)
; 12(2): 511-527, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35038128
5.
Interim 2-Year Analysis from SERENA: A Real-World Study in Patients with Psoriatic Arthritis or Ankylosing Spondylitis Treated with Secukinumab.
Rheumatol Ther
; 9(4): 1129-1142, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35674938
6.
Multifaceted Sexual Dysfunction in Dialyzing Men and Women: Pathophysiology, Diagnostics, and Therapeutics.
Life (Basel)
; 11(4)2021 Apr 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33918412
7.
Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study.
Adv Ther
; 37(6): 2865-2883, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32378070